Corante

About this author
Zack Lynch is author of The Neuro Revolution: How Brain Science Is Changing Our World (St. Martin's Press, July 2009).
He is the founder and executive director of the Neurotechnology Industry Organization (NIO) and co-founder of NeuroInsights. He serves on the advisory boards of the McGovern Institute for Brain Research at MIT, the Center for Neuroeconomic Studies, Science Progress, and SocialText, a social software company. Please send newsworthy items or feedback - to Zack Lynch.
Follow me on Twitter at @neurorev
Receive by email

GUEST AUTHOR ARCHIVES
THE NEURO REVOLUTION
TNRCoverWeb120.jpg Buy on Amazon
In the Pipeline: Don't miss Derek Lowe's excellent commentary on drug discovery and the pharma industry in general at In the Pipeline

Brain Waves

« Medicalizing Road Rage | Main | An Oxytocin - Not Oil - Shortage »

July 5, 2006

Emerging Addiction Treatments - Neurotech Insights

Email This Entry

Posted by Zack Lynch

This month's Neurotech Insights is focused on the addiction market and includes:

Top News Alerts: Product Updates, Deals & Financings across neurotechnology
Featured Topic: Addiction Treatment and Clinical Trials

Featured Company: Alkermes (ALKS)

MARKET SUMMARY: TARGACEPT AND NORTHSTAR ADDED TO NEUROTECH INDEX

Neurotech%20Insights%20June%2030%202006%20Addiction_Page_01%20sm.jpgAmarin (AMRN) was the top gainer this month after recovering from profit taking in May. The company has shown continued progress in their pipeline, including completion of enrollment in the Phase III trial of Miraxion for Huntington’s disease. Endo Pharmaceuticals (ENDP) saw gains after announcing the launch of Synera anesthetic patch and approval of Opana (see page 4 & 5). Medivation (MDV), a company developing the neuroprotectant Dimebon for Alzheimer’s disease, gained ground after investors took speculative note of upcoming Phase II trial announcements…



EMERGING TREATMENTS FOR ADDICTION

There is no consistent, universally accepted definition of addiction. In the minds of many, addiction is synonymous with substance abuse but behaviors such as compulsive gambling, compulsive shopping, and even compulsive video gaming that do not involve the use of exogenous substances have also been described as addictions. Many view a common underlying dysfunction in so-called impulse control and reward pathways in the brain as the key event in both drug addiction and behavioral addiction. The reward pathways involve many neurotransmitters and modulators, but some are of particular interest...

ALKERMES: MORE THAN A DRUG DELIVERY COMPANY

Alkermes (ALKS) was founded by Michael Wall, an electrical engineer and Floyd Bloom, a neuroscientist, with the aim of finding a way to get drugs past the blood brain barrier. It was the late 80s and the scientists were eager to do for neuroscience what had been done for cardiovascular disease. Only the so-called blood brain barrier was blocking the way for most pharmaceuticals to get into the brain. By 1991, when CEO Richard Pops joined, the company had 20 people and it was in the clinic with a compound for brain malignancies, called gliomas…

Subscribe now for these articles and much much more...

Comments (2) + TrackBacks (0) | Category: NeuroInsights


COMMENTS

1. Kensai on July 12, 2006 3:54 PM writes...

Indeed, addiction seems one of the big markets.
But what happens if we get "addicted" in addiction treatments?! :/

Constantine

Permalink to Comment

2. Anonymous on October 17, 2007 4:13 AM writes...

Nice

Permalink to Comment


EMAIL THIS ENTRY TO A FRIEND

Email this entry to:

Your email address:

Message (optional):




RELATED ENTRIES
Chinese Cover of The Neuro Revolution
The Neuro Revolution Lands In China
How Neuroscience Will Change the World - My Interview on Reason.tv
Neuroscience Hearing on Capitol Hill Wednesday Sept 29, 2pm
The Neuro Revolution Published in Japan as "Neuro Wars"
Neurotech 2010: Translational Researchers Highlight Innovation
The Neuro Revolution in China Progressing
Speakers for Neurotech 2010 - Boston, May 19-20